Medical network - February 20, according to statistics, in 2016 the global top 10 best-selling drug sales is expected to total 83.121 billion dollars, an account for six seats, occupy 65.1%. The 2016 global sales of the size of the top 5 single resistant varieties are: Ada wood sheet resistance, infliximab (remicade, according to the heap, sheet resistance, rituxan, beacizumab bead sheet resistance. Sheet resistance to drugs of several major applications, antitumor and anti rheumatism proportion is the largest.
With more than 2016-2019 global blockbuster single drug patents have expired, coupled with the country of biotech drugs industry policy support, will further boost domestic enterprises generic enthusiasm, an industry will usher in rapid development in our country. Resistance is expected in 2016 China's single market size is 8.3 billion yuan, the foreign capital enterprise products with nearly four to share.
At present, the world has listed more than 60 single resistance products only 10 listed on the domestic approval, the domestic single market has great potential for growth.
Repair the merlot: water with ease
Ada wood sheet resistance by American AbbVie (AbbVie) development, commodity called "Humira", in January 2003 for the first time listed for rheumatoid arthritis. After repairing the merlot indications extend to other autoimmune diseases, including psoriatic arthritis, ankylosing spondylitis, crohn's disease, psoriasis, juvenile idiopathic arthritis and ulcerative colitis, indications in the future will continue to widen.
In 2003, according to the world's bestselling drug data statistics, wood single sales were $280 million, 2015 sales of $14.001 billion. From 2005 to 2016, the product annual compound growth rate of 25.3%. The drug face U.S. patents expire in December 2016, the pharmaceutical giant amgen, Merck and Pfizer in the development of generic drugs. In 2017, according to forecast of merlot biosimilars will enter the U.S. market, 2018 will be the most difficult one year.
Sample according to the domestic hospital statistics, Ada wood single sales of 940000 yuan in 2010, 2015 annual sales of 23.85 million yuan, 2016 years ago in the third quarter sales is only 14.02 million yuan, is expected in 2016 sales of nearly 20 million yuan. Since the product at ease in domestic market growth is relatively slow.
Ada wood sheet resistance by abbott laboratories in 2010 listed on the import in our country, approved for treatment of rheumatoid arthritis, 2013 approved to alleviate active related symptoms and symptoms of ankylosing spondylitis patients.
The current domestic many medicine enterprises are Ada wood single generic development, declare the fastest progress is currently the Thai biological and cinda, have entered the clinical Ⅲ period. Flicker in addition, Beijing bamboo biological, jia and biological, jiangsu the medicine, corning jerry, macro han lam and zhejiang sea have been approved for clinical, in addition, there are more than 10 enterprises have already declared clinical trials generics.
At present, the most notable is the "huahai pharmaceutical Ada wood sheet resistance. In 2013, huahai pharmaceutical Oncobiologics company signed with the United States biological medicine strategic alliances and partnerships, joint ventures, joint development, and the technology license agreement. At the end of 2015, American strategic partners Oncobiologics huahai advised, Ada wood single American Ⅰ clinical end resistance, directly into the clinical Ⅲ period. At the same time, the company announced that with the United States Oncobiologics cooperation agreement about Ada wood sheet resistance change, huahai will choose public transfer enjoy Ada wood sheet resistance of its 51% interest in Europe and the United States and other countries market, focus on the domestic market development.
Grace: similar products occupy space
According to the heap, developed by the U.S. amgen won FDA approval in 1998, commodity called "Enbrel. This product is the world's first approved TNF inhibitors, is the world's first approved for use in ankylosing spondylitis treatment TNF inhibitors. In October 2012, Enbrel patents expire, but amgen won a new patent, can make the Enbrel patent protection until 2028. Enbrel biosimilars European patent expired in 2015, the generic products preempted the spondylitis, psoriasis and arthritis treatment market. Notable is: amgen in November 2016 in accordance with the heap to get FDA approval for chronic moderate to severe plaque psoriasis treatment of pediatric patients.
According to the world's bestselling drug data statistics, in 1999, according to the heap sales were $367 million, 2014, global sales peaked at $8.941 billion, annual sales of $2015 and $8.697 billion, is expected to sales as high as $8.54 billion in 2016, fell 1.8%. 2005-2016 annual compound growth rate of 8.0%. The drug European patent expires in 2015, global sales fell slightly over the last two years.
According to samples of domestic hospital data statistics, in accordance with the heap 2010 annual sales of 2.45 million yuan, 2015 annual sales of 16.92 million yuan, 2016 years ago in the third quarter sales of 15.68 million yuan, a 28.5% increase from the same period, is expected to 2016 annual sales of 20.15 million yuan. Treatment due to the product on the market relatively late, cost is higher, and not in the realm of health care, pharmaceutical giants for into the domestic interested in is not very big. But under the pull of the rigid demand in the domestic market, many domestic enterprises for the product market expectations.
In accordance with the heap by Pfizer in 2010 approved by CFDA in domestic market, commodity called "benefit" and dosage forms of powder injection, specifications, there is a 25 mg, this product is for domestic approved indications. Rheumatoid arthritis and ankylosing spondylitis. The current domestic similar products have injected with human recombinant Ⅱ type of tumor necrosis factor receptor antibody fusion protein, developed by citic countries health company, approved in 2005, goods is called "yi's", dosage forms of powder injection, specification is 12.5 mg, 25 mg. At present, the domestic in addition to citic's health benefit match, two other approved listed respectively is 2011 Shanghai gold "chuck" and in 2015, the sea is pharmaceutical hundred, "" Ann. To obtain the approval documents of clinical trials of an enterprise and the qilu pharmaceutical, double heron pharmaceutical and suzhou gold au, clover biological declared clinical trials.
Class c: nearly 10 years in the domestic market growth is not obvious
Hideo, single treatment developed by Johnson &johnson, commodity called "Remicade", listed in the U.S. in October 1998, for the treatment of moderately severe crohn's disease. Main indications include: crohn's disease, rheumatoid arthritis, ulcerative colitis, mandatory spondylitis, psoriasis, etc., the drug is controlling drug rheumatism disease. The drug European patent expired in 2014, the United States patent expires in 2018, will face more generic competition.
According to the world's bestselling drug data statistics, infliximab (remicade, 1999 single sales were $150 million, annual sales of $2015 and $8.355 billion, 2016 annual sales in excess of $8.141 billion, down 2.6% compared with over the same period. From 2005 to 2016, the product annual compound growth rate of 7.8%.
Sample according to the domestic hospital statistics, hideo advantages of resistance to 2007 annual sales of 720000 yuan, 2015 annual sales of 110 million yuan, 2016 years ago in the third quarter sales is only 88.23 million yuan, is expected in 2016 sales of nearly 120 million yuan. The product has been a steady growth since the ease in domestic market. Hideo single treatment was the first to enter the clinical use of biological agents, market growth is not obvious in the recent ten years.
Hideo advantages of resistance to import listed by the strong, was born in 2007 in our country, commodity called "g", dosage forms of powder injection, the specification is 100 mg, psoriasis approved indications in China. This product does not have to enter national health care or medicine directory, similar drugs lack in China, but the drug price is relatively high, with no approved separately used in the treatment of rheumatoid arthritis, so clinical use will be limited. Infliximab (remicade, currently an approved clinical analogues of enterprises with Shanghai mai Po, and biological and sea are pharmaceutical. |
